Radiotherapy-assisted tumor selective metronomic oral chemotherapy

Seung Woo Chung, Seho Kweon, Beom Suk Lee, Gui Chul Kim, Foyez Mahmud, Hanul Lee, Young Seok Cho, Jeong Uk Choi, Ok Cheol Jeon, Ji Won Kim, Seong Who Kim, In-San Kim, Sang Yoon Kim, Youngro Byun

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chemotherapy have commonly been used in maximum tolerated dose to completely eradicate the cancer. However, such treatments often failed due to the complex and dynamic nature of cancer. Therefore, it has been suggested that cancer should be treated as a chronic disease, controlling its growth by providing continuous therapeutic pressure for long-term. Such an approach, however, requires a therapy that is non-toxic and orally available with sufficient potency. Herein, we propose a radiotherapy-assisted orally available metronomic apoptosis-targeted chemotherapy, which delivers doxorubicin continuously to the irradiated tumor with high selectivity while causing minimal toxicities to the normal tissues. DEVD-S-DOX/DCK complex is the anticancer prodrug for our strategy that could selectively release doxorubicin in the irradiated tumor tissue with sufficient oral bioavailability. The prodrug was completely inactive by itself, but displayed potent anticancer activity when coupled with radiotherapy. Consequently, the daily oral administration of DEVD-S-DOX/DCK in combination with the low-dose radiotherapy effectively suppressed the growth of tumor in vivo with no significant systemic toxicities despite that the accumulated dose of doxorubicin exceeded 150 mg/kg. Therefore, the our novel therapy using DEVD-S-DOX/DCK complex is considered as an outstanding treatment option for treating cancer for long-term attributed to its oral availability and low-toxicity profile as well as the potent anticancer effect.

Original languageEnglish
Pages (from-to)1912-1920
Number of pages9
JournalInternational Journal of Cancer
Volume141
Issue number9
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

Radiotherapy
Drug Therapy
Neoplasms
Doxorubicin
Prodrugs
Therapeutics
Maximum Tolerated Dose
Growth
Biological Availability
Oral Administration
Chronic Disease
Apoptosis
Pressure

Keywords

  • drug delivery system
  • metronomic therapy
  • oral chemotherapy
  • radiation-induced apoptosis-targeted chemotherapy
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chung, S. W., Kweon, S., Lee, B. S., Kim, G. C., Mahmud, F., Lee, H., ... Byun, Y. (2017). Radiotherapy-assisted tumor selective metronomic oral chemotherapy. International Journal of Cancer, 141(9), 1912-1920. https://doi.org/10.1002/ijc.30842

Radiotherapy-assisted tumor selective metronomic oral chemotherapy. / Chung, Seung Woo; Kweon, Seho; Lee, Beom Suk; Kim, Gui Chul; Mahmud, Foyez; Lee, Hanul; Cho, Young Seok; Choi, Jeong Uk; Jeon, Ok Cheol; Kim, Ji Won; Kim, Seong Who; Kim, In-San; Kim, Sang Yoon; Byun, Youngro.

In: International Journal of Cancer, Vol. 141, No. 9, 01.11.2017, p. 1912-1920.

Research output: Contribution to journalArticle

Chung, SW, Kweon, S, Lee, BS, Kim, GC, Mahmud, F, Lee, H, Cho, YS, Choi, JU, Jeon, OC, Kim, JW, Kim, SW, Kim, I-S, Kim, SY & Byun, Y 2017, 'Radiotherapy-assisted tumor selective metronomic oral chemotherapy', International Journal of Cancer, vol. 141, no. 9, pp. 1912-1920. https://doi.org/10.1002/ijc.30842
Chung SW, Kweon S, Lee BS, Kim GC, Mahmud F, Lee H et al. Radiotherapy-assisted tumor selective metronomic oral chemotherapy. International Journal of Cancer. 2017 Nov 1;141(9):1912-1920. https://doi.org/10.1002/ijc.30842
Chung, Seung Woo ; Kweon, Seho ; Lee, Beom Suk ; Kim, Gui Chul ; Mahmud, Foyez ; Lee, Hanul ; Cho, Young Seok ; Choi, Jeong Uk ; Jeon, Ok Cheol ; Kim, Ji Won ; Kim, Seong Who ; Kim, In-San ; Kim, Sang Yoon ; Byun, Youngro. / Radiotherapy-assisted tumor selective metronomic oral chemotherapy. In: International Journal of Cancer. 2017 ; Vol. 141, No. 9. pp. 1912-1920.
@article{f2c241548b8b408d9e83b29bd4de9edf,
title = "Radiotherapy-assisted tumor selective metronomic oral chemotherapy",
abstract = "Chemotherapy have commonly been used in maximum tolerated dose to completely eradicate the cancer. However, such treatments often failed due to the complex and dynamic nature of cancer. Therefore, it has been suggested that cancer should be treated as a chronic disease, controlling its growth by providing continuous therapeutic pressure for long-term. Such an approach, however, requires a therapy that is non-toxic and orally available with sufficient potency. Herein, we propose a radiotherapy-assisted orally available metronomic apoptosis-targeted chemotherapy, which delivers doxorubicin continuously to the irradiated tumor with high selectivity while causing minimal toxicities to the normal tissues. DEVD-S-DOX/DCK complex is the anticancer prodrug for our strategy that could selectively release doxorubicin in the irradiated tumor tissue with sufficient oral bioavailability. The prodrug was completely inactive by itself, but displayed potent anticancer activity when coupled with radiotherapy. Consequently, the daily oral administration of DEVD-S-DOX/DCK in combination with the low-dose radiotherapy effectively suppressed the growth of tumor in vivo with no significant systemic toxicities despite that the accumulated dose of doxorubicin exceeded 150 mg/kg. Therefore, the our novel therapy using DEVD-S-DOX/DCK complex is considered as an outstanding treatment option for treating cancer for long-term attributed to its oral availability and low-toxicity profile as well as the potent anticancer effect.",
keywords = "drug delivery system, metronomic therapy, oral chemotherapy, radiation-induced apoptosis-targeted chemotherapy, targeted therapy",
author = "Chung, {Seung Woo} and Seho Kweon and Lee, {Beom Suk} and Kim, {Gui Chul} and Foyez Mahmud and Hanul Lee and Cho, {Young Seok} and Choi, {Jeong Uk} and Jeon, {Ok Cheol} and Kim, {Ji Won} and Kim, {Seong Who} and In-San Kim and Kim, {Sang Yoon} and Youngro Byun",
year = "2017",
month = "11",
day = "1",
doi = "10.1002/ijc.30842",
language = "English",
volume = "141",
pages = "1912--1920",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Radiotherapy-assisted tumor selective metronomic oral chemotherapy

AU - Chung, Seung Woo

AU - Kweon, Seho

AU - Lee, Beom Suk

AU - Kim, Gui Chul

AU - Mahmud, Foyez

AU - Lee, Hanul

AU - Cho, Young Seok

AU - Choi, Jeong Uk

AU - Jeon, Ok Cheol

AU - Kim, Ji Won

AU - Kim, Seong Who

AU - Kim, In-San

AU - Kim, Sang Yoon

AU - Byun, Youngro

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Chemotherapy have commonly been used in maximum tolerated dose to completely eradicate the cancer. However, such treatments often failed due to the complex and dynamic nature of cancer. Therefore, it has been suggested that cancer should be treated as a chronic disease, controlling its growth by providing continuous therapeutic pressure for long-term. Such an approach, however, requires a therapy that is non-toxic and orally available with sufficient potency. Herein, we propose a radiotherapy-assisted orally available metronomic apoptosis-targeted chemotherapy, which delivers doxorubicin continuously to the irradiated tumor with high selectivity while causing minimal toxicities to the normal tissues. DEVD-S-DOX/DCK complex is the anticancer prodrug for our strategy that could selectively release doxorubicin in the irradiated tumor tissue with sufficient oral bioavailability. The prodrug was completely inactive by itself, but displayed potent anticancer activity when coupled with radiotherapy. Consequently, the daily oral administration of DEVD-S-DOX/DCK in combination with the low-dose radiotherapy effectively suppressed the growth of tumor in vivo with no significant systemic toxicities despite that the accumulated dose of doxorubicin exceeded 150 mg/kg. Therefore, the our novel therapy using DEVD-S-DOX/DCK complex is considered as an outstanding treatment option for treating cancer for long-term attributed to its oral availability and low-toxicity profile as well as the potent anticancer effect.

AB - Chemotherapy have commonly been used in maximum tolerated dose to completely eradicate the cancer. However, such treatments often failed due to the complex and dynamic nature of cancer. Therefore, it has been suggested that cancer should be treated as a chronic disease, controlling its growth by providing continuous therapeutic pressure for long-term. Such an approach, however, requires a therapy that is non-toxic and orally available with sufficient potency. Herein, we propose a radiotherapy-assisted orally available metronomic apoptosis-targeted chemotherapy, which delivers doxorubicin continuously to the irradiated tumor with high selectivity while causing minimal toxicities to the normal tissues. DEVD-S-DOX/DCK complex is the anticancer prodrug for our strategy that could selectively release doxorubicin in the irradiated tumor tissue with sufficient oral bioavailability. The prodrug was completely inactive by itself, but displayed potent anticancer activity when coupled with radiotherapy. Consequently, the daily oral administration of DEVD-S-DOX/DCK in combination with the low-dose radiotherapy effectively suppressed the growth of tumor in vivo with no significant systemic toxicities despite that the accumulated dose of doxorubicin exceeded 150 mg/kg. Therefore, the our novel therapy using DEVD-S-DOX/DCK complex is considered as an outstanding treatment option for treating cancer for long-term attributed to its oral availability and low-toxicity profile as well as the potent anticancer effect.

KW - drug delivery system

KW - metronomic therapy

KW - oral chemotherapy

KW - radiation-induced apoptosis-targeted chemotherapy

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85026669195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026669195&partnerID=8YFLogxK

U2 - 10.1002/ijc.30842

DO - 10.1002/ijc.30842

M3 - Article

C2 - 28635011

AN - SCOPUS:85026669195

VL - 141

SP - 1912

EP - 1920

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 9

ER -